期刊
LEUKEMIA
卷 33, 期 12, 页码 2817-2829出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41375-019-0495-8
关键词
-
资金
- Bloodwise [12068]
- Medical Research Council (MRC DTG)
- Children with Cancer UK [14-169]
- National Institute for Health Research University College London BRC Senior Clinical Research Fellowship
- Alternative Hair Charitable Foundation
- Great Ormond Street Hospital Children's Charity
- KIKA
- Great Ormond Street Hospital Children's Charity [V1305, V2617]
- NIHR Great Ormond Street Hospital Biomedical Research Center
Subtype-specific leukemia oncogenes drive aberrant gene expression profiles that converge on common essential mediators to ensure leukemia self-renewal and inhibition of differentiation. The transcription factor c-MYB functions as one such mediator in a diverse range of leukemias. Here we show for the first time that transcriptional repression of myeloid differentiation associated c-MYB target genes in AML is enforced by the AAA+ ATPase RUVBL2. Silencing RUVBL2 expression resulted in increased binding of c-MYB to these loci and their transcriptional activation. RUVBL2 inhibition resulted in AML cell apoptosis and severely impaired disease progression of established AML in engrafted mice. In contrast, such inhibition had little impact on normal hematopoietic progenitor differentiation. These data demonstrate that RUVBL2 is essential for the oncogenic function of c-MYB in AML by governing inhibition of myeloid differentiation. They also indicate that targeting the control of c-MYB function by RUVBL2 is a promising approach to developing future anti-AML therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据